QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

Amy Puenpatom  1     Ping Xu  2     Anjela Tzontcheva  2     Tony Terzis  3     Alan Meehan  4     Cindy L J Weinstein  2    
1 Merck & Co., Inc.,Upper Gwynedd,United States
2 Merck & Co., Inc.,Rahway,United States
3 MSD Switzerland,Kriens,Switzerland
4 Merck & Co., Inc.,Kenilworth,United States

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing